Ryan MacDonald: Helpful. And maybe just a follow-up. I wanted to ask about PAM. Obviously, it’s a longer-term opportunity here. But given the inclusion of the MIPS calculation this year, just curious how you’re going about sort of trying to get that in the hands of more physicians to sort of really start to drive that greater usage to create more maybe opportunities for 2026 and beyond.
Chaim Indig : So just for everyone’s edification, the PAM is the patient activation measure, and it’s a performance measure that we are the owner of the license. From a go-to-market motion, there’s a whole team that’s really working with our provider clients in getting it live and on. We’re performing to hundreds of thousands of PAMs on a regular basis. I think we have a lot of clients that have already put up their hands, we’re always adding more. And that body of work is still in its early stages. And I’m getting to know now we already have over 1 million unique patients that have done a PAM. So we feel good that the body of work and the data that we’re going to start producing will help further the — our view and generally in the walk community skew that — driving activation drives better outcomes. All across the board.
Balaji Gandhi : Yes. And Ryan, in addition to the MIPS program that you mentioned, we have spent a lot of time with the kidney care community, the Kidney Care Choices program, and we’re — help them drive a lot of great results, we think.
Operator: Our next question comes from the line of Aaron Kimson with Citizens JMP.
Aaron Kimson: I’m sure you guys saw that general catalyst announced its intent to buy [indiscernible] in Northeast Ohio in January, with the thesis of kind of building modern tech-enabled health care delivery platforms at scale. So Chaim, I’m wondering if you could share your thoughts on nonprofit network slipping before profit over time and the opportunities and risks you see there for Phreesia. And then secondly, from a patient care perspective, and as someone, frankly, who was born in that health care system and grew up in it, I’m curious how you think about the potential of these types of transactions to drive better patient outcomes?
Chaim Indig : All right. So I’m going to tread carefully on this because I tend not to publicly give a lot of issues. But I would say that whether it’s a health system is nonprofit, by tax [indiscernible] or for profit, I think they still have to be able to provide great care and they do often and not, frankly, do it at a loss make, right? So that they could keep operating the business. And what we’re really talking about the difference between for-profit and nonprofit is the tax status. But we have — if you look at ambulatory care across the country, there’s unbelievably dedicated professionals that operate in a for-profit manner that deliver care across the manner, and there’s nonprofits. And I think America’s health care system is able to support both nonprofit and for-profit care delivery systems.
And there’s — like — we have clients in the for-profit space that are just doing amazing work for their clients — into their patients. So I actually think it has more to do with the organization than its tax status.
Operator: There are no further questions. I will now turn the call back over to our team for closing remarks.
Chaim Indig : All right. I want to thank everyone for listening and supporting Phreesia, and we look forward to seeing all of you in the coming months. And I hope everyone has a really nice spring, and I’ll talk to all — Balaji and [indiscernible] — talk to you soon.
Balaji Gandhi : Thank you.
